{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:09:23Z","timestamp":1781284163972,"version":"3.54.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Goserelin is a gonadotropin-releasing hormone agonist for ovarian function suppression in the treatment of pre- and perimenopausal patients with breast cancer and for the preservation of ovarian function during chemotherapy. Goserelin is available in doses of 3.6 mg once every 4 weeks or 10.8 mg once every 12 weeks. This study used US real-world evidence to characterize goserelin treatment patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Electronic health record data of adults with a history of breast cancer and \u22652 goserelin prescriptions between January 1, 2017, and December 31, 2022, were identified through TriNetX. Patient demographics and treatment patterns were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Overall, 3,620 US patients were identified: 2,870 treated with goserelin 3.6 mg once every 4 weeks, 410 treated with 10.8 mg once every 12 weeks, and 340 switched from 3.6 mg once every 4 weeks to 10.8 mg once every 12 weeks. Peak utilization of 10.8 mg once every 12 weeks (36.6%) and dose switching to 10.8 mg once every 12 weeks (26.5%) occurred in 2020. Patients who switched to 10.8 mg once every 12 weeks had the longest median treatment duration (776 days), compared with the 3.6 mg once every 4 weeks and 10.8 mg once every 12 weeks cohorts (264 and 429 days, respectively). Of patients who switched, 65% were still being treated after 2 years, compared with 30% and 40% treated with 3.6 mg once every 4 weeks only or 10.8 mg once every 12 weeks only, respectively. Patients initially treated with or who switched to 10.8 mg once every 12 weeks were more adherent (64.4%-75.0%), compared with patients treated with 3.6 mg once every 4 weeks (45.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Treatment with goserelin 10.8 mg once every 12 weeks is associated with greater adherence and longer treatment duration, compared with 3.6 mg once every 4 weeks in patients with breast cancer in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-24-00655","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:59:09Z","timestamp":1747843149000},"page":"263-273","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-6242","authenticated-orcid":false,"given":"Kelly E.","family":"McCann","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-8458","authenticated-orcid":false,"given":"Virginia","family":"Kaklamani","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5630-874X","authenticated-orcid":false,"given":"Noran","family":"Osman","sequence":"additional","affiliation":[{"name":"TerSera Therapeutics LLC, Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cannon","sequence":"additional","affiliation":[{"name":"TerSera Therapeutics LLC, Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7232-7208","authenticated-orcid":false,"given":"Lonnie","family":"Brent","sequence":"additional","affiliation":[{"name":"TerSera Therapeutics LLC, Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-3347","authenticated-orcid":false,"given":"Rachel","family":"Lucia","sequence":"additional","affiliation":[{"name":"IQVIA Inc, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[{"name":"IQVIA Inc, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4190-2304","authenticated-orcid":false,"given":"Nicole","family":"Duran","sequence":"additional","affiliation":[{"name":"IQVIA Inc, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Gupta","sequence":"additional","affiliation":[{"name":"IQVIA Inc, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Martin","sequence":"additional","affiliation":[{"name":"TerSera Therapeutics LLC, Deerfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21718"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21695"},{"key":"e_1_3_8_5_2","volume-title":"Hormone Therapy for Breast Cancer","author":"American Cancer Society","year":"2024","unstructured":"American Cancer Society: Hormone Therapy for Breast Cancer, 2024. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment\/hormone-therapy-for-breast-cancer.html"},{"key":"e_1_3_8_6_2","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2024. \u00a9 National Comprehensive Cancer Network Inc 2024. All rights reserved. To view the most recent and complete version of the guidelines go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01360"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(11)60210-1"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02292-3"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.0858"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413204"},{"key":"e_1_3_8_12_2","volume-title":"ZOLADEX\u00ae (goserelin implant). Prescribing Information","author":"TerSera Therapeutics LLC","year":"2023","unstructured":"TerSera Therapeutics LLC: ZOLADEX\u00ae (goserelin implant). Prescribing Information, 2023. https:\/\/documents.tersera.com\/zoladex-us\/3.6mg_MagnumPI.pdf"},{"key":"e_1_3_8_13_2","volume-title":"ZOLADEX 3.6 mg Implant SmPC","author":"European Medicines Compendium","year":"2024","unstructured":"European Medicines Compendium: ZOLADEX 3.6 mg Implant SmPC, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/1543\/smpc#about-medicine"},{"key":"e_1_3_8_14_2","unstructured":"European Medicines Compendium: ZOLADEX LA 10.8 SmPC 2023. https:\/\/www.medicines.org.uk\/emc\/product\/1567\/smpc#gref"},{"key":"e_1_3_8_15_2","unstructured":"Health Canada: ZOLADEX\u00ae (3.6 mg goserelin depot) Product Monograph 2017. https:\/\/pdf.hres.ca\/dpd_pm\/00042728.PDF"},{"key":"e_1_3_8_16_2","unstructured":"TerSera Canada: Health Canada approves ZOLADEX\u00ae LA for the management of estrogen receptor-positive (ER+)early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women 2024. https:\/\/documents.tersera.com\/pressrelease\/ZoladexLA_050724_EN.pdf"},{"key":"e_1_3_8_17_2","volume-title":"Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Professionals","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention: Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Professionals, 2024. https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1695"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.03.002"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2023.05.010"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01967"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00557"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1332-y"},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","unstructured":"Wang Y Wang X Wu J et al: 123P Goserelin 10.8 mg and 3.6 mg depots in breast cancer (BC): A large real-world noninferiority study ESMO Open Volume 9 103111 2024. https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00879-2\/fulltext","DOI":"10.1016\/j.esmoop.2024.103111"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101335"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0637-4"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.243"},{"key":"e_1_3_8_28_2","article-title":"Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients","volume":"41","author":"Blotta DA","year":"2023","unstructured":"Blotta DA, Gomes JR, Moreira SBR, et al: Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients. J Clin Oncol 41, 2023 (suppl; abstr 527)","journal-title":"J Clin Oncol"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-00655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:59:30Z","timestamp":1770937170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-00655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/OP-24-00655"],"URL":"https:\/\/doi.org\/10.1200\/op-24-00655","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2024-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}